Feinberg Cardiovascular Research Institute, Northwestern University, Tarry 12-703, 303 East Chicago Avenue, Chicago, IL 60611, USA.
Microvasc Res. 2010 May;79(3):200-6. doi: 10.1016/j.mvr.2010.01.012. Epub 2010 Feb 6.
Cell-based therapy has emerged as a promising therapeutic tool for treatment of ischemic cardiovascular disease. Both unselected bone marrow-derived mononuclear cells (BMNCs), which include stem/progenitor cells and several other cell types, and endothelial progenitor cells (EPCs), a subpopulation of BMNCs, display regenerative potential in ischemic tissue. Abundant evidence supports the involvement of EPCs in capillary growth, and EPCs also appear to participate in the formation of collateral vessels. Collectively, these effects have led to improved perfusion and functional recovery in animal models of myocardial and peripheral ischemia, and in early clinical trials, the therapeutic administration of EPCs to patients with myocardial infarction or chronic angina has been associated with positive trends in perfusion. EPCs also contribute to endothelial repair and may, consequently, impede the development or progression of arteriosclerosis. This review provides a brief summary of the preclinical and clinical evidence for the role of EPCs in blood-vessel formation and repair during ischemic cardiovascular disease.
细胞疗法已成为治疗缺血性心血管疾病的一种有前途的治疗手段。未选择的骨髓来源的单核细胞（BMNCs），包括干细胞/祖细胞和几种其他细胞类型，以及内皮祖细胞（EPCs），是 BMNCs 的一个亚群，在缺血组织中显示出再生潜力。大量证据支持 EPCs 参与毛细血管生长，EPCs 似乎也参与侧支血管的形成。这些作用共同导致了动物模型中心肌和外周缺血的灌注和功能恢复的改善，并且在早期临床试验中，将 EPC 治疗性给药给心肌梗死或慢性心绞痛患者与灌注的积极趋势相关。EPCs 也有助于内皮修复，因此可能阻止动脉硬化的发展或进展。本文综述了 EPC 在缺血性心血管疾病期间血管形成和修复中的作用的临床前和临床证据。
